At Delta Hat we provide consultancy services to the pharmaceutical industry, act as a NICE EAG in collaboration with PenTAG at the University of Exeter, and provide statistical support to the SMC.
We produce high quality deliverables, and take pride in the communication of our work through submission dossiers, EAG reports, conference proceedings, and publications.
We offer a tailored service to each of clients by ensuring our teams have appropriate experience and time to complete the required tasks.
We encourage an open exchange of ideas and suggestions with a focus on pragmatic solutions, adapting our communication methods to best cater to our clients’ needs to meet project objectives. We have experience across a vast array of disease areas, ranging from haematology, oncology and chronic diseases through to CAR-T therapies and ultra-rare orphan indications.
We offer a range of modelling services including:
We encourage including a model conceptualisation step in our projects, as we find it to be incredibly valuable in the modelling process.
Health Technology Assessment
The Delta Hat team has extensive experience in HTA, collectively contributing to over 100 assessments through submission writing, modelling, provision of statistical analysis, post-submission support, advisory boards and other ad-hoc methodological and strategic support.
Primarily, we offer HTA submission support to the UK, including:
Statistical Data Analysis
Across the Delta Hat team, we have considerable knowledge and experience performing statistical analysis for economic modelling and HTA submissions including:
We regularly provide support to clients through independent considered advice, including:
If you’d like any further information about the services we offer, please get in touch: email@example.com.
Key: EAG, external assessment group; HTA, health technology assessment; NICE, National Institute for Health and Care Excellence; PenTAG, Peninsula Technology Assessment Group; SMC, Scottish Medicines Consortium; UK, United Kingdom.